Nick Challoner appointed CEO of Ingenza to drive further growth
Ella Day | July 4, 2025 | Appointment | Business Services, Manufacturing and Production | CEO, Corporate, Ingenza, contract research development and manufacturing organisation (CRDMO), president
Ingenza, a Scottish contract research, development and manufacturing organisation (CRDMO), has announced the appointment of Nick Challoner as chief executive officer, effective October 2025. With over three decades of leadership in chemical and biotech industries, Challoner’s arrival marks a key milestone in Ingenza’s growth strategy.
Challoner most recently served as group chief scientific officer at FTSE 100 firm Croda International, where he led global R&D strategy and delivered sustainable innovation across biotechnology and chemicals. During his tenure, he built a biotechnology programme, advancing multi-organism strain engineering and biocatalysis. In particular, he played a critical role in scaling and securing regulatory approval for Croda’s lipid delivery systems, key components in the Pfizer/BioNTech Comirnaty COVID-19 vaccine, contributing to $300m in sales.
At Ingenza, Challoner will focus on strengthening the company’s position as a strategic CRDMO partner and expanding its innovation pipeline. He succeeds company founder Ian Fotheringham, who steps into the role of president, dedicating more time to technology strategy and business development.
Executive chair Ian Shott commented: “Nick is an exceptional leader with the rare combination of strategic vision, scientific insight and commercial execution. His appointment comes at a pivotal stage for Ingenza’s global growth.”
Challoner added: “I am excited to lead the team as we build on our strengths and create transformative solutions for our partners.”
Ingenza’s platform uses advanced gene design, scalable bioprocessing and precision analytics to accelerate product development across biopharma, industrial enzymes and consumer applications.
Ella Day
4/7/25
Related Content
BioDuro and Silicogenix collaborate to advance non-traditional drug development
BioDuro, a contract research, development and manufacturing organisation, has announced a strategic partnership with small …
CEO of PixarBio Corporation sentenced to prison for defrauding investors
Frank Reynolds, the CEO of Boston based PixarBio Corporation, was sentenced to seven years in …
FibroGen rocked by unexpected death of CEO Thomas B Neff
In a saddening turn of events, San Francisco-based FibroGen has announced that Thomas B Neff, …
